bioAffinity Technologies (NASDAQ:BIAF) Stock Price Down 4.9% – Here’s What Happened

bioAffinity Technologies, Inc. (NASDAQ:BIAF)’s stock price traded down 4.9% on Friday . The stock traded as low as $1.13 and last traded at $1.17. 115,248 shares were traded during mid-day trading, an increase of 77% from the average session volume of 65,077 shares. The stock had previously closed at $1.23.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on BIAF. Wall Street Zen cut shares of bioAffinity Technologies to a “strong sell” rating in a research note on Saturday, September 20th. Weiss Ratings restated a “sell (e+)” rating on shares of bioAffinity Technologies in a report on Wednesday, October 8th. One analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Reduce”.

bioAffinity Technologies Stock Performance

The company has a debt-to-equity ratio of 0.01, a quick ratio of 3.64 and a current ratio of 3.65. The firm’s 50-day moving average price is $1.80 and its two-hundred day moving average price is $5.38. The stock has a market cap of $5.27 million, a price-to-earnings ratio of -0.06 and a beta of 2.41.

bioAffinity Technologies (NASDAQ:BIAF) last released its quarterly earnings data on Friday, November 14th. The company reported ($2.70) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($2.70). The firm had revenue of $1.45 million during the quarter, compared to analysts’ expectations of $1.41 million. bioAffinity Technologies had a negative net margin of 217.45% and a negative return on equity of 425.87%.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in bioAffinity Technologies stock. Scientech Research LLC bought a new position in shares of bioAffinity Technologies, Inc. (NASDAQ:BIAF) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 16,583 shares of the company’s stock, valued at approximately $49,000. Scientech Research LLC owned about 0.46% of bioAffinity Technologies as of its most recent SEC filing. 1.64% of the stock is owned by institutional investors and hedge funds.

bioAffinity Technologies Company Profile

bioAffinity Technologies, Inc (NASDAQ: BIAF) is a U.S.-based biotechnology company specializing in the development and commercialization of advanced in vitro diagnostic platforms for oncology. Leveraging proprietary bioaffinity and nanotechnology approaches, bioAffinity’s platforms are designed to isolate and analyze cancer-specific biomarkers from blood, tissue, and other biological samples with high sensitivity and specificity. The company’s core technologies aim to enable earlier detection of solid tumors, improved disease monitoring, and more personalized treatment strategies.

The company’s primary product pipeline includes assays targeting breast cancer and other solid tumor indications.